# Sebby Borriello

> Sebby Borriello is a pharmaceutical and medical-device commercialization veteran with 30-plus years of go-to-market leadership. After 25 years at Johnson & Johnson across wound management, biosurgery and aesthetics, he helped turn South Korea's SK Life Science from an R&D-only shop into a fully integrated US pharma company, leading the 2020 launch of its first FDA-approved drug, the epilepsy treatment XCOPRI. He later advised and joined Carmell Therapeutics as Chief Business Officer, and today serves as Executive Vice President and Chief Commercial Officer at MIDAS Healthcare Solutions, a New York startup tackling medication diversion and drug-waste accountability through its MidasVIEW platform and Anytime Witness video-verification technology.

- **Role:** Executive Vice President & Chief Commercial Officer at MIDAS Healthcare Solutions, Inc.
- **Organizations:** MIDAS Healthcare Solutions, Inc., Carmell Therapeutics, SK Life Science, Inc., Cempra, Mentor Worldwide LLC, Johnson & Johnson Healthcare Systems Inc., Ethicon, Inc., Ortho-McNeil Pharmaceuticals, Inc.
- **Nationality:** American
- **Education:** B.A., Public Administration, St. John's University, M.S., Organizational Dynamics, University of Pennsylvania
- **Known for:** Led the successful US launch of XCOPRI (cenobamate) in May 2020, executed virtually amid the COVID-19 pandemic., Helped transform SK Life Science from a drug-discovery/R&D entity into a fully integrated US commercial pharmaceutical company., Built out a US commercial sales organization planned at roughly 100-125 representatives.

## Career timeline

- **1981** — Earns B.A. in Public Administration from St. John's University.
- **1980s-2000s** — Roughly 25 years at Johnson & Johnson companies (Ortho-McNeil, Ethicon, J&J Healthcare Systems) across wound management, biosurgery and aesthetics.
- **2001** — Completes M.S. in Organizational Dynamics at the University of Pennsylvania.
- **2016** — Joins SK Life Science to evolve it from an R&D-only entity into a commercial organization.
- **2020** — Leads the virtual US launch of XCOPRI (cenobamate), SK Life Science's first FDA-approved, independently commercialized product, during the COVID-19 pandemic.
- **2021** — Begins serving as a Commercial/BD advisor to Carmell Therapeutics.
- **2022** — Appointed Chief Business Officer at Carmell Therapeutics.
- **2023** — Becomes Executive Vice President & Chief Commercial Officer at MIDAS Healthcare Solutions.

## Achievements

- Led the successful US launch of XCOPRI (cenobamate) in May 2020, executed virtually amid the COVID-19 pandemic.
- Helped transform SK Life Science from a drug-discovery/R&D entity into a fully integrated US commercial pharmaceutical company.
- Built out a US commercial sales organization planned at roughly 100-125 representatives.
- Spent about 25 years in commercial leadership at Johnson & Johnson across wound management, biosurgery and aesthetics franchises.
- Supported the commercial side of work tied to SK's major 2020 South Korean biotech IPO.
- Drives commercial strategy at MIDAS Healthcare Solutions for medication-diversion prevention and drug-waste accountability.

## Latest updates

- **2023-04** — Joined MIDAS Healthcare Solutions as Executive Vice President & Chief Commercial Officer, leading commercial strategy for its medication-diversion-prevention platform.

## Links

- Website: https://midashs.com
- LinkedIn: http://www.linkedin.com/in/sebbyborriello

---

Profile page: https://yespress.io/sebby-borriello
Published by YesPress — https://yespress.io
Last updated: 2026-06-20